Added to YB: 2025-08-29
Pitch date: 2025-07-07
GRAL [bullish]
GRAIL, Inc.
+101.42%
current return
Author Info
No bio for this author
Company Info
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Market Cap
$3.1B
Pitch Price
$45.09
Price Target
310.00 (+241%)
Dividend
N/A
EV/EBITDA
-7.92
P/E
-6.85
EV/Sales
18.49
Sector
Biotechnology
Category
growth
GRAIL, Inc. - $GRAL
GRAL: Multi-cancer early detection via Galleri blood test. 50+ cancers, 99.5% specificity, 137K tests sold 2024. FDA pivotal trial (35K pts) + NHS trial (140K pts) underway. Statistical analysis shows p<0.00001 significance. $900M EV vs $150B+ TAM. Base $145 (+270%), Bull $310 (+700%) on approval + reimbursement. Risk: no FDA MCED precedent.
Read full article (3 min)